We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.48%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.7B
AUM Growth
+$1.25B
Cap. Flow
-$79.9M
Cap. Flow %
-0.68%
Top 10 Hldgs %
34.47%
Holding
156
New
27
Increased
33
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$208M
2
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
+$109M
3
BMY icon
Bristol-Myers Squibb
BMY
+$74.8M
4
BLUE
bluebird bio
BLUE
+$56.1M
5
CAH icon
Cardinal Health
CAH
+$54.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$191M
2
AGN
Allergan Inc
AGN
+$158M
3
MRK icon
Merck
MRK
+$149M
4
BIIB icon
Biogen
BIIB
+$113M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$106M

Sector Composition

Rank Sector Weight
1 Healthcare 83.37%
2 Technology 0.15%
3 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
A icon
26
Agilent Technologies
A
$39.6B
$168M 1.44%
4,051,000
– –
MCK icon
27
McKesson
MCK
$106B
$161M 1.38%
713,000
-29,000
-4% -$6.43M
AGN
28
CALL
DELISTED
Allergan plc
AGN
$149M 1.27%
+500,000
New +$143M
ZBH icon
29
Zimmer Biomet
ZBH
$18.7B
$144M 1.23%
1,264,840
-56,341
-4% -$6.43M
TRNX
30
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$126M 1.08%
4,805,000
– –
TSRO
31
DELISTED
TESARO, Inc.
TSRO
$118M 1.01%
2,057,700
+727,700
+55% +$34.3M
ESRX
32
DELISTED
Express Scripts Holding Company
ESRX
$116M 0.99%
1,333,000
-974,000
-42% -$81.7M
ACT.PRA
33
DELISTED
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
$105M 0.9%
+104,200
New +$109M
PFE icon
34
Pfizer
PFE
$144B
$104M 0.89%
3,145,136
+237,150
+8% +$7.54M
SYK icon
35
Stryker
SYK
$135B
$103M 0.88%
1,113,000
+81,400
+8% +$7.58M
MGLN
36
DELISTED
Magellan Health Services, Inc.
MGLN
$100M 0.86%
1,414,800
+206,800
+17% +$13M
MNK
37
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$100M 0.86%
791,001
+224,000
+40% +$25.6M
ALXN
38
DELISTED
Alexion Pharmaceuticals
ALXN
$98M 0.84%
565,700
+233,700
+70% +$42.3M
AFFX
39
DELISTED
Affymetrix Inc
AFFX
$92.3M 0.79%
7,351,000
+783,000
+12% +$9.09M
LAB icon
40
Standard BioTools
LAB
$325M
$89.9M 0.77%
2,136,200
– –
PBYI icon
41
Puma Biotechnology
PBYI
$398M
$87.4M 0.75%
370,200
+119,300
+48% +$25.5M
CAH icon
42
Cardinal Health
CAH
$54.6B
$86.7M 0.74%
960,000
+635,000
+195% +$54.7M
OTIC
43
DELISTED
Otonomy, Inc.
OTIC
$79.8M 0.68%
2,256,398
– –
ISEE
44
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$77.6M 0.66%
1,668,600
+806,800
+94% +$41.9M
CLVS
45
DELISTED
Clovis Oncology, Inc.
CLVS
$74.3M 0.63%
1,000,400
+286,300
+40% +$20.2M
INSY
46
DELISTED
Insys Therapeutics, Inc.
INSY
$72.3M 0.62%
2,486,400
– –
ARRY
47
DELISTED
Array Biopharma Inc
ARRY
$68M 0.58%
9,232,310
+1,984,610
+27% +$14.1M
TEVA icon
48
Teva Pharmaceuticals
TEVA
$39.8B
$68M 0.58%
1,091,000
+691,000
+173% +$40.2M
PODD icon
49
Insulet
PODD
$11.9B
$66.6M 0.57%
1,997,000
– –
BLUE
50
DELISTED
bluebird bio
BLUE
$66.5M 0.57%
+42,514
New +$56.1M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2015 Portfolio in Review

As of Q1 2015, OrbiMed held 156 positions worth $11.7B, up 12% from $10.5B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2015 filing shows 27 new, 33 increased, 24 reduced and 20 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M. The largest sale was Vertex Pharmaceuticals, an estimated $191M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier, followed by Technology and Financials.

  • OrbiMed's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M.
  • OrbiMed added most to Boston Scientific in Q1 2015, an estimated $208M increase.
  • OrbiMed's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $191M.
  • OrbiMed fully exited Allergan Inc in Q1 2015, selling an estimated $158M.
  • OrbiMed's ten largest holdings make up 34% of its $11.7B portfolio in Q1 2015.
  • OrbiMed opened 27 new positions and closed 20 in Q1 2015.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $11.7B.

Based on OrbiMed's 13F filing for Q1 2015, filed 15 May 2015.